AstraZeneca has made a billion-dollar swoop for French MedTech Amolyt Pharma. Amolyt Pharma is a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. The acquisition bolsters Alexion, AstraZeneca’s rare disease late-stage pipeline, and expands on its bone metabolism franchise. Under the terms of the agreement, AstraZeneca has acquired all of Amolyt … Continue reading AstraZeneca in billion-dollar swoop